MASTER Trial: Prospective, multicentre, randomized trial evaluating the MGuard stent in the treatment of patients with acute myocardial infarction with ST segment elevation (STEMI).

Foreword: The EPS MGUARD stent (embolic protection stent) has a fine metal structure covered by a thin polyethylene fiber mesh with pores of 5 microns wrapping the stent that might prevent distal embolization during primary angioplasty and would therefore be particularly attractive during primary angioplasty.

Methods and Results: We included 432 patients referred for primary angioplasty having 70% ST). In two thirds of the population we used a predilatation thromboaspiration catheter and predilatation reached 50%. The MGuard direct implantation was 12% and 10.6% in the conventional group (p = NS). The MGuard group had a higher rate of final TIMI III (91.7% versus 82.9%, p = 0.006) and ST resolution (57.8% versus 44.7%, p = 0.008). The MGuard group showed a tendency to have lower cardiac mortality at 30 days (0 versus 1.9%, p = 0.06), with no observed difference in the rate of reinfarction, thrombosis or emergency reintervention.

Conclusion: The MGuard stent in a primary angioplasty context is associated with a better rate of ST resolution and final TIMI III flow. Studies with a larger sample size are needed to confirm the preliminary results observed in this randomized study.

Read article

Descargar (PDF, Unknown)

Gregg Stone.
2012-10-24

Original title: The MASTER Trial a prospective, randomized, multicenter evaluation of a PET Micronet Mesh Covered Stent (MGuard) in STEMI.

*

Top